275 related articles for article (PubMed ID: 17224656)
1. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
2. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
Crispino JD
Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
[TBL] [Abstract][Full Text] [Related]
3. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
4. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
5. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
6. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
7. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
8. [The role of GATA1 mutation in acute megakaryocytic leukemia].
Ito E
Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
[No Abstract] [Full Text] [Related]
9. Transcription factor GATA-1 and Down syndrome leukemogenesis.
Muntean AG; Ge Y; Taub JW; Crispino JD
Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
[TBL] [Abstract][Full Text] [Related]
10. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
[No Abstract] [Full Text] [Related]
11. Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21.
Hoeller S; Bihl MP; Tzankov A; Chaffard R; Hirschmann P; Miny P; Kühne T; Bruder E
Hum Pathol; 2014 May; 45(5):1003-9. PubMed ID: 24746204
[TBL] [Abstract][Full Text] [Related]
12. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
Kim IS; Park ES; Lim JY; Ki CS; Chi HS
J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
[TBL] [Abstract][Full Text] [Related]
14. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
[TBL] [Abstract][Full Text] [Related]
15. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
16. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
[TBL] [Abstract][Full Text] [Related]
17. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
[TBL] [Abstract][Full Text] [Related]
18. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
19. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
Shimizu R; Kobayashi E; Engel JD; Yamamoto M
Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
[TBL] [Abstract][Full Text] [Related]
20. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]